Conflicting results from 2 randomized trials testing Tocilizumab for Covid-19

Study 1: Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia – New England Journal of Medicine

Study 2: Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup – New England Journal of Medicine

Commentary on Twitter

Why do 2 randomized trials of tocilizumab, an interleukin-6 blocker, for severe covid-19, have opposite results?
Today @NEJMhttps://t.co/g8LCrhhpLyhttps://t.co/BcN3wOwsl0 pic.twitter.com/sLrQUYI1pf

— Eric Topol (@EricTopol) February 25, 2021